Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker.
The development of anti-tumor necrosis factor (TNF) therapies is a milestone in the therapy of rheumatic diseases. It is of concern whether all potential undesired complications of therapy have been evaluated within clinical trials which have led to treatment approval. Specialists prescribing TNF blockers should be aware of the unusual and severe complications that can occur. We describe a case of endogenous endophthalmitis in a rheumatoid patient on TNF alpha blocker.
Agarwal
Pankaj Kumar
PK
Department of Ophthalmology, Lanarkshire Acute Hospital Trust, East Kilbride, Glasgow, United Kingdom. pankaj_eye@yahoo.com
Gallaghar
Mick
M
Murphy
Elizabeth
E
Virdi
Meena
M
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003937:Diagnosis, Differential; D009877:Endophthalmitis / Q000175:diagnosis / Q000382:microbiology* / Q000473:pathology; D015818:Eye Infections, Bacterial / Q000139:chemically induced*; D005260:Female; D006801:Humans; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014463:Ultrasonography
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab